We are in the final weeks to join leading experts from the FDA, industry, and academia at CHI’s 17th Annual Immunogenicity & Bioassay Summit. Explore the latest strategies in immunogenicity risk assessment, preclinical and clinical development, and bioassay design and analysis. Discover how to harness the immune system for therapeutic benefit through cutting-edge case studies, novel insights, and innovative approaches.
This year’s summit features:
- Three focused conference tracks a symposium, training seminar, and five short courses (two new for 2025!)
- Interactive breakout discussions on specialized topics to foster collaboration and idea sharing
- A dynamic exhibit and poster hall showcasing the latest products, technologies, and services
Speakers from the FDA are strongly represented each year, providing critical regulatory perspectives alongside leaders from Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and other top organizations.
Whether you're looking to overcome challenges in immunogenicity testing or enhance your bioanalytical strategy, this summit provides the knowledge, connections, and tools to move your programs forward. We look forward to welcoming you this fall in Alexandria, VA!